Ms. Sudha Moparthy

 Ms. Sudha Moparthy |Clyto Access

Research Associate, Roswell Park Cancer Institute, New York

Poster Presentation

Expertise: cancer biology, melanoma, multiple myeloma

Biography: Ms. Sudha Moparthy  carried her M.S in Biochemistry and Environmental, Safety & Occupational Health Management. Later she started working as a Research Associate in Internal Medicine- Pulmonary & Critical Care at University of Michigan. Presently she is working as a Research Associate in Department of Cell Stress Biology at Roswell Park Cancer Institute, New York,

Presentation:

Title: KLF9-TXNRD2 AXIS in Regulation of Oxidative and Endoplasmic Reticulum Stresses

Abstract:

Cellular responses to oxidative and endoplasmic reticulum (ER) stress are among the most evolutionarily conserved pathways within the cell. Tumor cells commonly encounter both ER and oxidative stress due to high levels of metabolism, including increased rates of protein translation. Yet drugs aimed primarily at interference with these stress response pathways comprise only a small portion of currently available anti-neoplastic agents. 
Moreover, little is known about the interrelating connection between ER stress and oxidative stress caused by these few anticancer drugs. For instance, it is generally accepted that intracellular oxidative stress induced by proteasome inhibitors is a byproduct of ER stress. Here, we report a mechanism underlying the ability of proteasome inhibitor bortezomib (BTZ) to directly induce both oxidative and ER stress in multiple myeloma (MM) cells via transcriptional repression of the gene encoding mitochondrial thioredoxin reductase (TXNRD2). TXNRD2 is critical for maintenance of intracellular redox status and detoxification of reactive oxygen species. 
Depletion of TXNRD2 to the levels detected in BTZ-treated cells causes oxidative stress, ER stress and death similar to those induced by proteasome inhibitors. Reciprocally, restoration of near-wildtype TXNRD2 levels in MM cells treated with proteasome inhibitors reduces oxidative stress, ER stress and cell death by ~46%, ~35% and ~50%, respectively, compared to cells with depleted TXNRD2 levels.  Moreover, cells from three MM cell lines selected for resistance to BTZ demonstrate elevated levels of TXNRD2, indirectly confirming its functional role in BTZ resistance.  
Accordingly, ectopic expression of TXNRD2 in MM cell xenografts in immunocompromised mice blunts the therapeutic effects of BTZ.  
Our data identifies KLF9-TXNRD2 axis as a potential clinically relevant target that is critical for proteasome inhibitor-dependent efficacy, cytotoxicity, oxidative stress, and ER stress. 
,

Related Conferences :

International Conference on Cancer Care and Cure